AAPL332.27+5.70 (+1.75%) ▲|ABBV257.12+2.12 (+0.83%) ▲|ABT101.95-1.41 (-1.36%) ▼|ACN183.90+5.99 (+3.37%) ▲|ADBE252.23+3.40 (+1.37%) ▲|AMAT456.49+2.48 (+0.55%) ▲|AMD516.13+12.53 (+2.49%) ▲|AMGN377.35-5.12 (-1.34%) ▼|AMT177.85+4.87 (+2.82%) ▲|AMZN256.78+4.89 (+1.94%) ▲|AVGO361.99+1.16 (+0.32%) ▲|AXP324.69+3.98 (+1.24%) ▲|BA210.45+5.65 (+2.76%) ▲|BAC62.69+0.13 (+0.21%) ▲|BKNG173.92+0.01 (+0.01%) ▲|BLK1,079.65+17.25 (+1.62%) ▲|BMY63.64-0.11 (-0.17%) ▼|BNY162.66+0.07 (+0.04%) ▲|BRK-B510.37+3.37 (+0.66%) ▲|C138.82+0.32 (+0.23%) ▲|CAT818.57+13.57 (+1.69%) ▲|CL86.80-1.10 (-1.25%) ▼|CMCSA25.20+0.03 (+0.12%) ▲|COF208.30+1.19 (+0.57%) ▲|COP137.35+0.31 (+0.23%) ▲|COST904.77+2.39 (+0.26%) ▲|CRM247.72+4.72 (+1.94%) ▲|CSCO112.13+4.69 (+4.37%) ▲|CVS94.66-0.63 (-0.66%) ▼|CVX214.06+1.30 (+0.61%) ▲|DE675.74-2.20 (-0.32%) ▼|DHR200.14-0.39 (-0.19%) ▼|DIS106.55+0.73 (+0.69%) ▲|DUK119.42+0.05 (+0.04%) ▲|EMR152.19+3.82 (+2.57%) ▲|FDX311.99+0.19 (+0.06%) ▲|GD355.90+1.65 (+0.47%) ▲|GE323.66-0.49 (-0.15%) ▼|GEV957.27+33.36 (+3.61%) ▲|GILD143.72-1.09 (-0.75%) ▼|GM85.62-0.50 (-0.58%) ▼|GOOG335.45+5.06 (+1.53%) ▲|GOOGL338.50+5.90 (+1.77%) ▲|GS1,029.18+9.41 (+0.92%) ▲|HD308.74+3.05 (+1.00%) ▲|HON202.36+0.18 (+0.09%) ▲|IBM243.29+9.27 (+3.96%) ▲|INTC102.94+2.62 (+2.61%) ▲|INTU321.57+8.80 (+2.81%) ▲|ISRG369.15+8.69 (+2.41%) ▲|JNJ265.58-0.77 (-0.29%) ▼|JPM356.23+2.67 (+0.76%) ▲|KO88.29+0.46 (+0.52%) ▲|LIN466.22+4.60 (+1.00%) ▲|LLY1,115.70-7.30 (-0.65%) ▼|LMT524.19-5.93 (-1.12%) ▼|LOW196.82+0.23 (+0.12%) ▲|LRCX298.22+0.21 (+0.07%) ▲|MA569.19+3.82 (+0.68%) ▲|MCD252.53-0.52 (-0.21%) ▼|MDLZ62.44-0.03 (-0.05%) ▼|MDT90.96-0.66 (-0.72%) ▼|META648.03+3.65 (+0.57%) ▲|MMM164.97+2.11 (+1.30%) ▲|MO68.98+0.19 (+0.28%) ▲|MRK143.93-0.78 (-0.54%) ▼|MS214.38+1.72 (+0.81%) ▲|MSFT495.63+3.19 (+0.65%) ▲|MU975.26-2.15 (-0.22%) ▼|NEE82.31-0.13 (-0.16%) ▼|NFLX77.40+1.39 (+1.83%) ▲|NKE36.80+0.18 (+0.49%) ▲|NOW132.53+1.36 (+1.04%) ▲|NVDA218.29-0.07 (-0.03%) ▼|ORCL150.28-2.66 (-1.74%) ▼|PEP136.32-0.33 (-0.24%) ▼|PFE27.72+0.07 (+0.25%) ▲|PG145.27+2.30 (+1.61%) ▲|PLTR167.23+1.37 (+0.83%) ▲|PM191.06+1.29 (+0.68%) ▲|QCOM181.97+5.09 (+2.88%) ▲|RTX197.68-0.44 (-0.22%) ▼|SBUX98.74-0.48 (-0.48%) ▼|SCHW107.25-0.08 (-0.07%) ▼|SO87.17-0.58 (-0.66%) ▼|SPG204.83+0.16 (+0.08%) ▲|T26.06+0.51 (+2.00%) ▲|TMO609.82+6.64 (+1.10%) ▲|TMUS182.33+5.17 (+2.92%) ▲|TSLA365.44+1.88 (+0.52%) ▲|TXN268.70+9.88 (+3.82%) ▲|UBER71.67-0.89 (-1.23%) ▼|UNH379.09-9.19 (-2.37%) ▼|UNP284.40-1.38 (-0.48%) ▼|UPS100.28+0.31 (+0.31%) ▲|USB62.84+0.43 (+0.69%) ▲|V370.45+3.24 (+0.88%) ▲|VZ50.61+0.64 (+1.28%) ▲|WFC90.29+0.84 (+0.94%) ▲|WMT107.15+1.42 (+1.34%) ▲|XOM165.99+0.76 (+0.46%) ▲|AAPL332.27+5.70 (+1.75%) ▲|ABBV257.12+2.12 (+0.83%) ▲|ABT101.95-1.41 (-1.36%) ▼|ACN183.90+5.99 (+3.37%) ▲|ADBE252.23+3.40 (+1.37%) ▲|AMAT456.49+2.48 (+0.55%) ▲|AMD516.13+12.53 (+2.49%) ▲|AMGN377.35-5.12 (-1.34%) ▼|AMT177.85+4.87 (+2.82%) ▲|AMZN256.78+4.89 (+1.94%) ▲|AVGO361.99+1.16 (+0.32%) ▲|AXP324.69+3.98 (+1.24%) ▲|BA210.45+5.65 (+2.76%) ▲|BAC62.69+0.13 (+0.21%) ▲|BKNG173.92+0.01 (+0.01%) ▲|BLK1,079.65+17.25 (+1.62%) ▲|BMY63.64-0.11 (-0.17%) ▼|BNY162.66+0.07 (+0.04%) ▲|BRK-B510.37+3.37 (+0.66%) ▲|C138.82+0.32 (+0.23%) ▲|CAT818.57+13.57 (+1.69%) ▲|CL86.80-1.10 (-1.25%) ▼|CMCSA25.20+0.03 (+0.12%) ▲|COF208.30+1.19 (+0.57%) ▲|COP137.35+0.31 (+0.23%) ▲|COST904.77+2.39 (+0.26%) ▲|CRM247.72+4.72 (+1.94%) ▲|CSCO112.13+4.69 (+4.37%) ▲|CVS94.66-0.63 (-0.66%) ▼|CVX214.06+1.30 (+0.61%) ▲|DE675.74-2.20 (-0.32%) ▼|DHR200.14-0.39 (-0.19%) ▼|DIS106.55+0.73 (+0.69%) ▲|DUK119.42+0.05 (+0.04%) ▲|EMR152.19+3.82 (+2.57%) ▲|FDX311.99+0.19 (+0.06%) ▲|GD355.90+1.65 (+0.47%) ▲|GE323.66-0.49 (-0.15%) ▼|GEV957.27+33.36 (+3.61%) ▲|GILD143.72-1.09 (-0.75%) ▼|GM85.62-0.50 (-0.58%) ▼|GOOG335.45+5.06 (+1.53%) ▲|GOOGL338.50+5.90 (+1.77%) ▲|GS1,029.18+9.41 (+0.92%) ▲|HD308.74+3.05 (+1.00%) ▲|HON202.36+0.18 (+0.09%) ▲|IBM243.29+9.27 (+3.96%) ▲|INTC102.94+2.62 (+2.61%) ▲|INTU321.57+8.80 (+2.81%) ▲|ISRG369.15+8.69 (+2.41%) ▲|JNJ265.58-0.77 (-0.29%) ▼|JPM356.23+2.67 (+0.76%) ▲|KO88.29+0.46 (+0.52%) ▲|LIN466.22+4.60 (+1.00%) ▲|LLY1,115.70-7.30 (-0.65%) ▼|LMT524.19-5.93 (-1.12%) ▼|LOW196.82+0.23 (+0.12%) ▲|LRCX298.22+0.21 (+0.07%) ▲|MA569.19+3.82 (+0.68%) ▲|MCD252.53-0.52 (-0.21%) ▼|MDLZ62.44-0.03 (-0.05%) ▼|MDT90.96-0.66 (-0.72%) ▼|META648.03+3.65 (+0.57%) ▲|MMM164.97+2.11 (+1.30%) ▲|MO68.98+0.19 (+0.28%) ▲|MRK143.93-0.78 (-0.54%) ▼|MS214.38+1.72 (+0.81%) ▲|MSFT495.63+3.19 (+0.65%) ▲|MU975.26-2.15 (-0.22%) ▼|NEE82.31-0.13 (-0.16%) ▼|NFLX77.40+1.39 (+1.83%) ▲|NKE36.80+0.18 (+0.49%) ▲|NOW132.53+1.36 (+1.04%) ▲|NVDA218.29-0.07 (-0.03%) ▼|ORCL150.28-2.66 (-1.74%) ▼|PEP136.32-0.33 (-0.24%) ▼|PFE27.72+0.07 (+0.25%) ▲|PG145.27+2.30 (+1.61%) ▲|PLTR167.23+1.37 (+0.83%) ▲|PM191.06+1.29 (+0.68%) ▲|QCOM181.97+5.09 (+2.88%) ▲|RTX197.68-0.44 (-0.22%) ▼|SBUX98.74-0.48 (-0.48%) ▼|SCHW107.25-0.08 (-0.07%) ▼|SO87.17-0.58 (-0.66%) ▼|SPG204.83+0.16 (+0.08%) ▲|T26.06+0.51 (+2.00%) ▲|TMO609.82+6.64 (+1.10%) ▲|TMUS182.33+5.17 (+2.92%) ▲|TSLA365.44+1.88 (+0.52%) ▲|TXN268.70+9.88 (+3.82%) ▲|UBER71.67-0.89 (-1.23%) ▼|UNH379.09-9.19 (-2.37%) ▼|UNP284.40-1.38 (-0.48%) ▼|UPS100.28+0.31 (+0.31%) ▲|USB62.84+0.43 (+0.69%) ▲|V370.45+3.24 (+0.88%) ▲|VZ50.61+0.64 (+1.28%) ▲|WFC90.29+0.84 (+0.94%) ▲|WMT107.15+1.42 (+1.34%) ▲|XOM165.99+0.76 (+0.46%) ▲|
24.3 C
New York
Saturday, September 12, 2026

Tag: pharmaceutical

newssourceFORcompanyinformationcontent1releasesmarket

Pharmaceutical Industry Calls on G7 to Prioritize Innovation as Strategic Pillar for Health, Growth and Security

GENEVA and OTTAWA, ON, June 12, 2025 /CNW/ - Ahead of the upcoming G7 Leaders' Summit, the global pharmaceutical industry, represented by the International...

Black Buffalo Strengthens Leadership with Kit Dietz’s Board Re-Election and Viv Penninti’s Appointment as Senior Advisor

CHICAGO, June 12, 2025 /PRNewswire/ -- Black Buffalo Inc., the leading alternative to traditional smokeless tobacco, proudly announces the re-election of Kit Dietz to...

Rebel Medicine Announces Series A Financing and Investigational New Drug (IND) Application Opening to Advance Non‑Opioid Pain Therapeutic into Clinical Development

SALT LAKE CITY, June 12, 2025 /PRNewswire/ -- Rebel Medicine Inc, a clinical‑stage biotechnology company developing innovative drug delivery systems and non‑opioid pain therapeutics...

Vascarta Receives FDA Orphan Drug Designation for Vasceptor® in the Treatment of Sickle Cell Disease

SUMMIT, N.J., June 12, 2025 /PRNewswire/ -- Vascarta Inc., a biopharmaceutical company committed to advancing innovative therapies for underserved patient populations, announced today that...

Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics

Vancouver, Canada, June 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

Protection through 2039, ensuring long-term commercial exclusivity. NEW YORK, June 12, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative...

Standard Industries Announces Molecule.one as Winner of $1 Million AI Challenge

Novel AI Application to Accelerate the Development and Production of Pharmaceuticals NEW YORK, June 12, 2025 /PRNewswire/ -- Standard Industries ("Standard"), a privately-held global industrial...

Sharecare introduces new interactive solutions to elevate health literacy and increase condition-specific treatment adherence

Utilizing augmented reality, artificial intelligence, and time-based visualization, Sharecare’s newest innovative tools help life sciences brands engage, educate, and activate patients 
Utilizing augmented reality, artificial intelligence, and time-based visualization, Sharecare’s newest innovative tools help life sciences brands engage, educate, and activate patients

Reacta Healthcare announces transformation into a facility for multi-allergen manufacturing

1st production of pharmaceutical grade egg and milk challenge mealsProduct portfolio of challenge meals now includes peanut, milk and eggInnovation pipeline includes development of...

BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer

MAINZ and TÜBINGEN, Germany, June 12, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and CureVac N.V. (Nasdaq: CVAC, “CureVac”) today announced that they have entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all of the shares of CureVac, a clinical-stage biotech company developing a novel class of transformative medicines in oncology and infectious diseases based on messenger ribonucleic acid (“mRNA”). The all-stock transaction will bring together two highly complementary companies based in Germany and will build on BioNTech’s proven track record and established position in the global mRNA industry.

Dizal Showcases Two First-in-Class Therapies in Hematologic Malignancies at EHA and ICML 2025

Golidocitinib demonstrated promising efficacy in maintaining and enhancing tumor response in peripheral T-cell lymphoma (PTCL) post first-line therapy with a 24-month disease-free survival (DFS)...

AstriVax Therapeutics Further Strengthens Team with the Appointment of Dieter Weinand as New Chair of the Board of Directors

Leuven, Belgium, June 12, 2025 – AstriVax Therapeutics NV, a clinical stage immunotherapy company developing novel treatments for chronic infections based on its proprietary Launch-iT technology, announced today the appointment of Dieter Weinand as Chair of the Board of Directors, effective June 12, 2025. Mr. Weinand is the former Chief Executive Officer of Bayer Pharma AG with more than 25 years of experience as a senior business leader in the pharmaceutical industry. He takes over from Dr. Jeanne Bolger, who served as Chair since 2022 and will remain on the Board as a non-executive independent director.

Kelun-Biotech’s Novel CLDN18.2 ADC SKB315 IND in Combination with Tagolizumab Receives NMPA Approval for the First-Line Treatment of Gastric/Gastro-oesophageal Junction Cancer

CHENGDU, China, June 11, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that the Company has received a clinical trial notice...

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-rknd) in adults with steroid refractory acute graft versus host disease (SR-aGvHD).

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPharmaceutical

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers